MSD (Merck & Co.) has recently doubled-down on its 72-acre campus with two linked builds that turbo-charges it's Asia-Pacific supply of oncology, vaccine and respiratory products.
🔷 Investment: Over the past number of years, MSD have invested close to US $500 million, lifting MSD’s lifetime spend in Singapore beyond US $2 billion.
🔷 The investment has included a secondary packaging + sterile fill-finish lines which opened in 2022 and an inhaler production plant for next-generation devices which is expected by by completed next year.
🔷>100 advanced-manufacturing roles have been added, taking headcount past 1,800 in the region
🔷The projects has resulted in a fully-automated packaging, an upgraded IT/OT stack and green-utilities spend align with MSD’s global sustainability roadmap.
PlantQuest Insight: MSD’s modular “add-on” strategy shows how brownfield hubs can be future-proofed for both biologics and combination devices—the environment where digital asset-visibility pays off.
At PlantQuest, we’re proud to spotlight initiatives that drive global pharmaceutical innovation. We look forward to supporting forward-thinking organisations like MSD as they set new benchmarks in manufacturing.
Explore our library of expert insights, tools, and resources to enhance your facility's performance and efficiency.
Biopharma facility integrates SAP PM facility with PlantQuest to transform task planning & execution.